Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-004882
Filing Date
2025-04-15
Accepted
2025-04-15 17:18:18
Documents
95
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1692059
2 ex4-2.htm EX-4.2 57575
3 ex21-1.htm EX-21.1 4791
4 ex23-1.htm EX-23.1 5068
5 ex31-1.htm EX-31.1 11457
6 ex31-2.htm EX-31.2 11348
7 ex32-1.htm EX-32.1 10593
8 ex97-1.htm EX-97.1 33477
  Complete submission text file 0001641172-25-004882.txt   7334142

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE mtnb-20241231.xsd EX-101.SCH 47880
10 XBRL CALCULATION FILE mtnb-20241231_cal.xml EX-101.CAL 77760
11 XBRL DEFINITION FILE mtnb-20241231_def.xml EX-101.DEF 182323
12 XBRL LABEL FILE mtnb-20241231_lab.xml EX-101.LAB 467015
13 XBRL PRESENTATION FILE mtnb-20241231_pre.xml EX-101.PRE 386208
97 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 868283
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38022 | Film No.: 25840570
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)